Avsar.

Healthcare · Pharmaceuticals

Senores Pharmaceuticals Ltd (SENORES)

₹1,387.50

Mkt cap
₹6,390 Cr
P/E ratio
55.40
P/B
6.83
Div yield
0.00%
ROE
13.40%
ROCE
15.10%
EPS (TTM)
₹25.05
Book value
₹203
52W range
609–1,481
Sector
Healthcare

Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities [1]

NSE SENORESBSE 544319www.senorespharma.com
Health check
Constructive
ValuationExpensive
ProfitabilityAverage
GrowthHigh
TechnicalsBullish
52-week range
−6.31% from high
₹1,388
₹609+127.85% from low₹1,481
Current
₹1,387.50
Prev close
₹1,390.00
Day
−0.18%
Price performance
1D
−0.18%
1W
+0.18%
1M
+9.28%
3M
+55.70%
6M
+76.85%
1Y
+123.00%
YTD
+60.35%

Financials

F
Revenue, profit & margin
P/E ratio
55.4×
SENORES is 63% above the sector median of 34.0×
SENORES55.4×
Sector median34.0×
 Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Trend
Sales7910280101103114138162171175
Expenses648059777795104112121128
Operating Profit15222123261934505047
OPM %19%22%27%23%25%17%25%31%29%27%
Other Income120251235718
Interest2355655658
Depreciation3444456889
Profit before tax10181316202126414547
Tax %31%19%19%18%20%13%20%26%25%23%
Net Profit7141113161821303437
EPS in Rs2.375.233.233.863.733.874.287.036.876.86
Raw PDF

Earnings

EResults dates & reactions
Next results
27 Jul '26scheduled

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

No reaction history yet.
No quarterly filings ingested yet.

Corporate actions

CLast 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Shareholding

Sas of Jun 2026
45.82%Promoter
Promoters45.82%
FIIs6.62%2.98
DIIs9.77%0.15
Public37.78%3.14
Ownership trend

Peers

P8 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
Sun Pharma.Inds.₹1,941.1037.484,65,7350.82%2,710+13.58%14,612+12.76%20.53%
Divi's Lab.₹7,248.5073.361,92,4250.41%751+13.44%2,831+9.52%21.97%
Torrent Pharma.₹4,961.5086.111,88,7200.77%364−20.58%4,197+41.84%15.19%
Cipla₹1,410.6031.841,13,9550.92%786−39.19%7,119+2.33%15.49%
Zydus Lifesci.₹1,108.7020.381,10,5930.09%1,341+21.92%7,587+16.22%21.14%
Lupin₹2,370.5019.061,08,3870.76%1,469+101.49%7,475+31.89%29.93%
Mankind Pharma₹2,507.2051.441,03,5460.04%559+34.23%3,443+11.81%13.53%
Senores Pharma.₹1,387.5055.396,3900.00%37+77.29%175+53.39%15.13%
Median: 157 Co.₹432.0534.031,9780.10%15+28.10%176+17.66%15.10%

Filings

D
Annual reports1
Financial Year 2025bse
Concall transcripts20
TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026PPTDec 2025TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptJul 2025PPTJul 2025RECJul 2025TranscriptMay 2025PPTMay 2025RECMay 2025PPTMay 2025TranscriptJan 2025PPTJan 2025RECJan 2025
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 21 Jul - Senores Pharmaceuticals Limited has informed regarding Earnings Conference Call for Q1FY27 scheduled to be held on July 27, 2026 at 05:15 P.M. (IST)Board Meeting Intimation for Considering And Approving The Unaudited Consolidated And Standalone Financial Results Of The Company For The Quarter Ended June 30, 2026 And To Transact Other Business Matters 21 Jul - Board meeting on July 27, 2026 to approve Q1 FY26 results; trading window remains closed.Submission Of Reconciliation Of Share Capital Audit Report For The Quarter Ended June 30, 2026 7 Jul - Submitted reconciliation of share capital audit report for quarter ended June 30, 2026.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Jul - Senores Pharmaceuticals Limited has informed regarding Certificate pursuant to Regulation 74(5) of SEBI (DP) Regulations, 2018 for quarter ended June 30, 2026Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Jul - Senores Pharmaceuticals Limited has informed regarding copy of Newspaper Publication